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CRYPTOCOCCOSIS: A REVIEW OF THE BRAZILIAN EXPERIENCE FOR THE DISEASE
Mara C.S.M. PAPPALARDO(1) & Márcia S.C. MELHEM(2)
SUMMARY
Cryptococcosis is a systemic mycosis caused by Cryptococcus neoformans. The disease occurs in patients with cellular
immunodeficiency. The incidence of cryptococcosis arises with AIDS, and mycosis is one of the opportunistic infections that defines
AIDS. After the HAART era the occurrence of cryptococcosis decreased all over the world, but it still continues to be a prevalent
disease in Brazil. Thus, we consider this paper to be very important as a result of our reviewing of Brazilian literature regarding some
relevant aspects of that disease.
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INTRODUCTION
Since the discovery of Cryptococcus by Sanfelice, 108 years has
passed by, and we know much about this capsulated yeast, but there are
many areas to be researched that evolve the interaction of the agent with
human host. Some aspects of this binomial are fascinating, but not exactly
clear. Some of these aspects of the history of disease, extremely modified
by acquired immunodeficiency syndrome (AIDS) and more recently by
highly active antiretroviral treatment (HAART). Other aspects are related
to the biology of the etiologic agent. The knowledge gained by the studies
of molecular biology and of antifungal sensitivity as well biochemical
studies about Cryptococcus neoformans virulence have contributed in
elucidating several points about that yeast. Studies had became more
intensive since the 80’s due to the epidemic AIDS and cryptococcosis
has became an important opportunistic infection due to both by increasing
the morbidity rates and mortality rates39,64.
Brazilian literature about cryptococcosis contributes significantly
due to the elucidation of related facts regarding the agent and the disease.
The aim of this study is to review the Brazilian literature, including
many unpublished theses that have new findings of great importance
and deserve being highlighted in reviews about cryptococcosis.
In Brazil, the honorable professor Dr. Carlos da Silva Lacaz and his
master, Dr. Floriano de Almeida, first reported cryptococcosis, here
describing the two first reports in 1941 and 1944 respectively, according
to REIS-FILHO et al.73.
Ecological and Epidemiological Aspects: Cryptococcosis is a
worldwide disease and its occurrence prior to the AIDS epidemic was
sporadic and generally associated to low cellular immunity. Currently,
cryptococcosis occurs in the general population in a relatively low
incidence taking in account the wide distribution of C. neoformans in
the environment that makes it possible to foresee a high probability of
spore inhalation5. Occurrence of subclinical, asymptomatic forms of the
disease is unknown and studies, such as cellular immunity surveys using
intradermic tests with the yeast antigen in patients without clinical disease
are rare, and therefore the extent of the subclinical form has not been
properly evaluated41,48. C. neoformans’ habitat in the environment is on
the ground, in decomposed vegetables, bird and bat feces which are
found both in urban and rural areas of Brazil3,5,7,27,47,50,55,58,59,66,67,75,89,90.
Studies of LAZERA et al.43,44,45,46 gave new dimensions to the ecology
of the cryptococcosis agent in Brazil demonstrating that yeast is
associated not only to Eucalyptus sp gender, but also to other species of
trees. The most appropriate methodology for C. neoformans isolation
from environment samples was well evaluated by MONTENEGRO &
PAULA55 and BARONI5 who successfully isolated two species of the
yeast in São Paulo and Rio de Janeiro, Brazil.
Infectious particles spread by air represent the most important source
of pulmonary contamination after inhalation, and there is no consensus
about its origin: whether or not it is sexual (basidiospores) or asexual
(conidia)39. Molecular studies with Brazilian samples showed that the
majority of infections are caused by heterothallic strains classified as α-
phenotypes (mating-type MATα) that are also prevalent in environmental
samples of C. neoformans6.
C. neoformans has five serotypes: A, B, C, D and AD of two varieties
called neoformans (A, D and AD) and gattii (B and C). FRANZOT et
al.30 proposed the reclassification of A-serotype into a new species: grubii.
Several epidemiological inquiries show the heterogeneous distribution
of these subtypes of cryptococcosis agents in several countries, verifying,
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consequently, the hypothesis of a correlation between etiologic agent
variety and geographic regions according to MELO et al.49. In Brazil,
the pioneer study of LACAZ & RODRIGUES40 showed that the majority
(64%) of 25 biological samples belonged to the neoformans variety with
the A-serotype prevailing followed by B and D. Predominance of this
serotype into our clinical setting was therefore, confirmed by other
authors both with biological and environmental samples10,11,12,32,52,53. The
possibility of transformation between A and AD-serotypes was reported
by BARRETO DE OLIVEIRA6 and REZENDE74. The gattii species are
endemic in the northeast of Brazil, which is responsible for 71% of
cases18.
Molecular studies about etiological agents contribute to the
comprehension of the Brazilian cryptococcosis epidemiology. An Iberian
American study done with strains from nine countries including Brazil
showed low genetic variability in 340 strains of C. neoformans being 56
clinical and 9 environmental samples. The methodology used was PCR
(Polymerase Chain Reaction) associated to RFLP (Restriction Fragment
Length Polymorphism) and it revealed only three molecular types of species
of Brazilian strains among the eight types of species identified in the study52.
FRANZOT et al. 29 suggested a clonal origin of strains acquired in Brazilian
cases explain the low genetic diversity observed among the 51 samples
collected from the cities of Belo Horizonte and Rio de Janeiro by way of
PFGE (Pulsed Field Gel Electrophoresis) and RFLP studies, and they
have pointed to important differences from North American strains. ALFP
(Amplified Fragment Length Polymorphism) methodology applied by
BOEKHOUT et al.8 has confirmed hybridism of C. neoformans.
VIVALDINI97 has verified by RAPD (Randomly Amplified Polymorphic
DNA) analysis great homogeneity among 89 clinical samples from the
São Jose do Rio Preto region, in accordance with a strong similarity of
genotypes previously described by ALMEIDA2. IGREJA33 has verified
very similar profiles evaluating 60 strains in Rio de Janeiro city. HORTA
et al.32 have applied RAPD technique in 17 clinical samples and 10
environmental samples from Rio Grande do Sul state, and they have verified
great differences in molecular profiles. REZENDE74, using the same
methodology but with other primers also verified genetic heterogeneity
without dominance of any molecular type species among clinical samples
collected in the cities of Araraquara and Ribeirão Preto, suggesting the
absence of a correlation among sources of infection. DNA profile studies
made it possible for REZENDE74 and IGREJA33 to demonstrate the
maintenance of the same agent through all the disease’s course even with
antifungal therapy in some cases. In one patient, IGREJA found mixed
infection with the two species, gattii and neoformans33.
Generally, C. neoformans var. gattii infects immunocompetent
individuals, such as primary or secondary diseases, in contrast to
var. neoformans, which has a strong association between the variety and
the immune host status36,85. In Brazil, as occurs in other countries,
cryptococcosis rates by gattii species in patients with AIDS are lower
than the population, with other underlying diseases, or even without
immunodepression, a data consistent with the worldwide
literature6,13,26,74,77,78,79,83,97. PAULA et al. 69 in a study of the cryptococcosis
agent, in 40 cases not associated to infection by HIV, demonstrated the
proportion of gattii of about 33% while in AIDS patients this rate is
below 1%51,58,62. CORREA et al.22 have observed alterations, through
tomographical images, in 11 immunocompetent children with infection
of the central nervous system (CNS) by gattii variety. In a study carried
out in Rio de Janeiro City, patients with AIDS exposed to spores of
C. neoformans species in a home environment have presented a risk to
cryptococcosis two times more than non-exposed AIDS patients66.
NISHIKAWA et al.58 published the most complete study to the
present, in which they proposed that the prevalence of neoformans species
is not homogeneous all over Brazil considering 467 environmental and
biological samples. The authors verified the prevalence of B-serotype as
the etiologic agent of non- AIDS patients in the northeast of Brazil.
Moreover, interesting data reveal the occurrence of C-serotype in negative
HIV patients and high rates of AD-serotypes (1.3%) in relation to D-
serotypes (0.4%) in the total samples.
Clinical and laboratorial aspects: The influence of agent variety
in disease prognosis was well studied by SEVERO86 that concluded a
positive correlation between disease caused by neoformans species and
death. The predisposed disease was AIDS (48%) or other diseases
associated to cellular deficiency (33%) in cases with neoformans species.
This and other aspects of agent and cryptococcosis diseases can be
appreciated in the excellent review published by the author87.
The yeast has a strong tropism to CNS but it can occur in localized
forms or the disseminated disease associated, or not to aids4,9,15,18,25,42,84,92,95.
Systemic forms of the disease are diverse and ZANINI et al.98 observed
ulcer as the first sign. Virulence of the agent invading different organs
and its participation in death can be verified in Brazilian studies using
histopathology analysis28,53,71. Meningoencephalitis is the most common
form of cryptococcosis infection. About 70% to 90% of patients with
AIDS and CNS cryptococcosis have signs and symptoms of sub acute
meningitis or meningoencephalitis as follows: headache, fever, lethargy,
coma, personality disorder and loss of memory which occurs 2-4 weeks
previous to diagnosis35. PAPPALARDO65 showed that in 35 patients the
following most common signs and symptoms of cryptococcosis were
apparent at the time of diagnosis: cephalea (97.1%), nausea and/or
vomiting (51.4%), fever (34.3%), visual disturbance (20%), altered
mental status (11.4%), seizure (8.6%) and menigeal signs (5.7%). The
same findings had been described but in different proportions by other
authors31,99. Cephalea is the second cause of pain in AIDS patients, and
CNS cryptococcosis is responsible for 40% of this symptom1.
The disease is more frequent in adults, but despite being rare it can
affect children. CORREA et al.21 considered that in Brazil there is an
increase of cryptococcosis rates in the childhood population considering
the incidence of 24.4% observed in the group of patients studied. DARZÉ
et al.24 reported a similar incidence of about 30% of 104 cases occurring
in the population of less than 15 years old. Cryptococcosis can be
associated to other mycoses especially oral candidiasis, dermatophytosis,
pityriasis versicolor and also to systemic mycoses, such as
paracoccidiodomycosis or histoplasmosis according to three cases of
AIDS reported by CAIUBY et al.10.
Laboratory diagnosis of CNS cryptococcosis can be done by cerebral
spinal fluid (CFS) examinations or by histopathological assay or even
by the polysaccharide capsular antigen test. Several Brazilian authors
have related chemocytologic aspects of CFS on cryptococcosis associated
or not to AIDS, but a specific pattern of the disease does not
exist24,35,72,73,92,93. The capsule, a morphologic aspect that distinguishes
the genre Cryptococcus sp is considered an important factor of yeast
virulence38; however, there are cases described of the disease caused by
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a non-capsulated agent or by low capsule production17,37,82. Other
virulence factors such as phenol oxidase production were studied in
clinical strains by REZENDE74. PAULA et al.70 proposed a sensitive
and economic procedure to evaluate the production capacity of that
enzyme. Phospholipases and proteinases are virulence related enzymes,
and SILVA88 found production rates of 84% and 20% respectively in
isolated samples from pigeon excrement. In two other papers,
REZENDE75 using samples from pigeon excrement and VIDOTTO et
al.96 using clinical strains, verified high production of phospholipase in
Brazilian strains suggesting that there is strong virulence.
As highlighted in the Brazilian literature, the best option for disease
diagnosis in terms of high sensitivity and quick results is the detection
of polysaccharide antigen by latex particle agglutination, in body fluids
such as: CSF, serum and urine. The disadvantage of this is that it is an
imported product and has a high cost12. The most economical and practical
diagnosis of CNS cryptococcosis is done by direct examination of CSF
sediment prepared with India ink which has a sensitivity of 96.3% in
AIDS cases13,73,77,94. The yeast count does not correlate with the antigen
titers but can indicate severity of disease12,65. The direct examination and
the culture can have discordant results12. Since no diagnostic method
has total sensitivity and specificity, a combination of several methods is
recommended. Culture and isolation of the agents is the gold standard
method having greater specificity and almost 100% sensitivity for
cryptococcosis diagnosis12,80. However, OLIVEIRA et al.63 in studies of
66 cases of CNS cryptococcosis showed insufficient use of culture method
as a diagnostic means, and they emphasized that sensitivity could vary
according to each laboratory. Isolation for gender and species
identification and confirmation of etiologic agent is done on agar for
analysis of morphologic and chemical features of yeast. Histological
analysis can be done with several dyes, the most commonly used being
hematoxylin-eosin dye and Gomori dye. Fontana-Masson dye is useful
in the identification of capsule-deficient yeast38,39.
Therapeutic aspects and antifungal sensitivity testing: Antifungals
used in cryptococcosis treatment are amphotericin B (AB), 5-flucytosine
(5-FC) and fluconazole (FZ)87. PASSOS et al.68 have studied ”in vitro”
the antifungal activity of a plant extract against the yeast. Meningeal
cryptococcosis-associated AIDS treatment is done in two phases: the
first one in the acute or induction phase, for six to 10 weeks or until CFS
becomes sterile. The second one is called the maintenance phase for an
indefinite period. Generally, authors consider two consecutive negative
results as criteria for determining the change from the induction phase
to the maintenance phase80. Usually AIDS patients are treated at the
initial phase with AB, with or without 5-FC, but relapses are very common
in 50% to 75% if the therapy is discontinued80,81. CAMPOS et al.16
revealed minor adverse effects, minor relapses and late death in cases
receiving AB therapy associated to 5-FC. Current tendency is the use of
high doses of AB, 0.7 mg/kg/day to 1 mg/kg/day during the first two
weeks of treatment associated to minor doses of 5-FC, 100 mg/kg/day,
followed by high doses of FZ, 800 mg/day for eight to 12 weeks. In the
maintenance phase 200 mg of FZ are administered, and with this regimen,
the cryptococcosis meningitis mortality in AIDS was decreased from
14-25% to 6%, according a classical North American study80.
The Department of Health in Brazil centralizes epidemiological data
about cryptococcosis as an opportunistic disease in the National Program
of Sexually Transmitted Diseases and AIDS. From 1980 to 2002 (April),
215,810 AIDS cases were registered with 6% of patients having
cryptococcosis at the time of diagnosis54. Cryptococcosis can be the first
opportunistic infection in AIDS, ranging from 23% to 48.6% according
to each study done12,65. The AIDS Bulletin entitled “Boletim AIDS - Cor
e Raça” which was published by the Reference and Training Center of
Sexual Transmitted Diseases and AIDS (Centro de Referência e
Treinamento em DST/AIDS) of the São Paulo State Health Secretary
showed that cryptococcosis rate associated to AIDS has been on the
average about 3.7% in the last 14 years (www.cvs.gov.sp.br). Data from
the Epidemiology Division at the Instituto de Infectologia Emílio Ribas
a specialized hospital in Infectious Diseases in São Paulo, Brazil, show
that CNS cryptococcosis in AIDS patients both in inpatients and
outpatients have generally decreased in the last few years: 7.7% in 1995;
7.4% in 1996; 8.2% in 1997; 6.8% in 1998; 5.8% in 1999, 4.6% in
2000, 3.1% in 2001, remaining unchanged up to April, 2002. At this
hospital, the induction phase of cryptococcosis treatment associated to
AIDS follows a guideline of a single therapy with AB, usually with a
maximum daily dose of 50 mg since, unfortunately the 5-FC drug was
unavailable on the Brazilian market for a while. Mortality ascribed to
cryptococcosis in 35 AIDS patients at Emilio Ribas Infectious Disease
Institute was 79%65. General mortality in cryptococcosis patients, with
or without underlying disease, is around 45% - 65%, according to
Brazilian studies12,28,31,35,60,61. A study of 17 cases of CNS cryptococcosis
showed that clinical aspects, follow-ups and necroscopy findings were
influenced by the presence and the kind of immunodeficiency, that is, a
worst prognosis being seen in patients with pre-existing primary disease,
such as, diabetes or neoplasia, in comparison to immunodepressed cases
under renal transplant therapy or immunocompetent patients28.
The most important predictive factor of early death is the patient
mental status at the time of diagnosis, but other factors are also applicable:
CSF antigen titer >1024, CFS cell count <20/mm3 and age <35 years
old80. Extraneural cryptococcosis, hypernatremia and high counts of
fungal cells are also parameters of poor prognosis80. Despite of being
important aspects for prognosis, intracranial hypertension (ICH) and
extraneural cryptococcosis were underdiagnosed according to a Brazilian
retrospective study65. Cryptococcemia in AIDS patients was observed in
6.6% of patients with clinical suspicion or previous history of CNS
cryptococcosis91. Major rates were verified by CÔRTES23 on analysis of
70 blood cultures of AIDS patients.
Besides factors that definitely contribute to therapeutic failure, there
are hypotheses for the existence of resistant phenotypes to therapy.
Resistant phenotypes are identified in populations of several etiologic
agents by means of sensitivity tests that can be done by several methods:
dilution in liquid medium, dilution and diffusion on agar medium.
Comparisons of test results obtained with agar and in liquid medium
were done worldwide as well as in Brazil, confirming the test vali-
dity14,19,20. The minimum inhibitory concentration (MIC) of the drug
against the etiologic agent is the most-used parameter for detecting
resistant strains. Since the 80’s, North American and European groups
were implicated in developing a reference method, the most important
being respectively, the NCCLS (National Committee for Clinical Labora-
tory Standards) and the EUCAST (European Committee on Antimicrobial
Susceptibility Testing) subcommittees56,76. The current method accepted
as reference for the “in vitro” antifungal susceptibility testing is the
M27-A2 document from NCCLS56. The proposed EUCAST metho-
dology has its guidelines based on NCCLS76. However, the M27-A2
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document has limitations in non-fermentative yeasts studies of glucose,
such as Cryptococcus sp, and therefore there are studies done by Brazilian
authors seeking adequate alternative test conditions for work with this
genera against natural or synthetic drugs2,57,65,74,97.
In several studies, the majority of C. neoformans human samples
are “in-vitro” sensitive to FZ and itraconazole (IZ); on the other hand,
up to 50% of the strains are resistant to 5-FC11,33,35,65,74. However,
VIVALDINI97 found clinical strains with less sensitivity to IZ, a fact
which was previously reported by ALMEIDA2. In another study
REZENDE74 reported around 18% of samples being less sensitive to FZ
in accordance with data from PAPPALARDO65 who found a resistance
of 12% in 168 samples collected from 35 patients.
In C. neoformans environmental samples, about 25% presented low
sensitivity to FZ while AB and IZ were the most effective antifungals5,55.
The difference of the “in-vitro” response to 5-FC between the two agent
varieties was noted by MONTENEGRO & PAULA55. The E-test method
was used by SILVA88 for analysis of 62 isolated strains of pigeon feces,
which were highly sensitive to AB, IZ and ketoconazole (KZ) and
resistant to FZ for the most part. ALVES & CURY3 observed less
sensitivity to FZ in clinical samples than in environmental samples and
to AB, IZ and KZ, the authors verifying high sensitivity of strains
independent of their origin.
Generally, C. neoformans strains, like the majority of yeasts, are
“in-vitro” sensitive to AB13,33,34,65,74. However, there are still serious
limitations concerning the credibility of results of testing this drug even
when using recommended methods74. Because of this and other problems,
the test results cannot be used in routine medical practice65. It is important
to highlight that there is no reference method for the carrying out of
susceptibility tests for the cryptococcosis agent and also there is a scarcity
of worldwide studies in the literature that correlate clinical prognosis to
yeast-sensitivity profile65. Therefore, there is inconsistency in the
correlation of therapy failure with the presence of “in-vitro” resistant C.
neoformans strains.
CONCLUSIONS
Existing data at this precise moment suggests that the main cause
for therapy failure in CNS cryptococcosis associated with AIDS is due
to the low immunity of the host. Moreover, little is known about the
antifungal pharmacokinetics in the CNS of the host in the presence of
ICH, or of the role of antifungal cell exo-enzymes, or the virulence of
the strain, or even of the genetic or physiologic mechanisms implicated
in the resistance of the etiologic agent. Even less is known about the role
of each one of these factors in the follow-up of cryptococcosis. The
research fields are numerous, and, given the stable morbidity and lethality
rates associated with AIDS in Brazil, despite the existence of HAART
and other advanced therapies, Brazilian researchers should contribute in
clarifying predictor variables of clinical improvement of cryptococosis.
RESUMO
Criptococose: revisão sobre a experiência brasileira sobre a doença
Criptococose é micose sistêmica causada por Cryptococcus
neoformans. A doença ocorre em pacientes com deficiência da imunidade
celular. Com o aparecimento da doença AIDS, a incidência de
criptococose aumentou, e a micose é uma das infecções oportunistas
que definem um caso de AIDS. Após a era HAART, criptococose parece
estar diminuindo no mundo todo, mas continua sendo uma doença
prevalente no Brasil. Este artigo visa a análise da contribuição dos autores
brasileiros sobre vários aspectos da doença.
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